FDA clarifies policies for compounders as national GLP-1 supply …
Oct 22, 2024 · The U.S. Food and Drug Administration has determined the shortage of tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, has been resolved.
New Multi-Society GLP-1 Clinical Practice Guidance Released
Oct 29, 2024 · CHICAGO – Most patients should continue taking their glucagon-like peptide-1 (GLP-1) receptor agonists before elective surgery, suggests new clinical guidance released by …
FDA Approves First Generic of Once-Daily GLP-1 Injection to …
FDA approved the first generic referencing Victoza (liraglutide injection) 18 mg/3 mL, a glucagon-like peptide-1 (GLP-1) receptor agonist indicated to improve glycemic control in...
Research shows GLP-1 drugs are effective but complex - UChicago …
May 30, 2024 · While experts caution against overusing GLP-1RAs or viewing them as a universal cure-all for obesity, physicians and researchers agree that the drugs are highly effective for …
GLP-1 Drug Liraglutide May Protect Against Dementia
PHILADELPHIA, July 30, 2024 — A glucagon-like peptide-1 (GLP-1) drug appears to slow cognitive decline by protecting the brain, according to Phase 2b clinical trial data reported …
Special Report: Potential Strategies for Addressing GLP-1 and Dual …
Apr 7, 2023 · Unexpected drug shortages of the long-acting glucagon-like peptide 1 (GLP-1) receptor agonists dulaglutide and semaglutide and the dual GLP-1/glucose-dependent …
New hope for binge eating and bulimia: GLP-1 drugs could be the …
Mar 4, 2024 · Glucagon-like peptide-1 (GLP-1) is a hormone and neuropeptide produced in the intestine and brain. This hormone inhibits appetite, reduces food intake, reduces body weight, …
Shortages impacting access to glucagon-like peptide 1 receptor …
Jan 29, 2024 · In the past year, global shortages of products indicated to manage diabetes type II and sometimes also approved for weight loss, known as glucagon-like peptide 1 receptor …
Glucagon-like peptide-1 receptor: mechanisms and advances in …
Sep 18, 2024 · We introduce recent studies that demonstrate the remarkable performance of GLP-1RAs in slowing the progression of neurodegenerative diseases, reducing inflammation, …
Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists
The development of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) has revolutionized the therapeutic landscape for cardiometabolic disease. Newer, more potent GLP-1 RAs (eg, …